MedTrace Logo

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

NCT06676527 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2025-12-05

No results posted yet for this study

Summary

This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.

Conditions

  • Neoplasms
  • Kidney Neoplasms
  • Urologic Neoplasms
  • Urogenital Neoplasms
  • Female Urogenital Diseases
  • Male Urogenital Diseases
  • Urogenital Diseases
  • Kidney Diseases
  • Urologic Diseases
  • Carcinoma
  • Renal Cell Cancer
  • Carcinoma, Renal Cell
  • Antineoplastic Agents

Interventions

OTHER

Follow-up study of the treated cohort

For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.

Sponsors & Collaborators

  • Jinling Hospital, China

    lead OTHER

Principal Investigators

  • Yuxiu Liu, M. D. · Jinling Hospital, China

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2026-09-01
Completion
2026-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06676527 on ClinicalTrials.gov